Clinical Trials

14 enrolled

CNSLymphoid

Primary Central Nervous System Lymphoma (PCNSL)

NCT04022980 2025-12-30

Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma

14 enrolled

Lymphoma, Neurologic Manifestations

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT02327078 2025-08-14

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

CNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidThoracic

307 enrolled 27 charts

Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT03739619 2025-08-06

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

3 enrolled 10 charts

Phase EARLY_PHASE1 Completed

Hodgkin Disease

NCT03311958 2025-04-06

Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance

15 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02631746 2025-03-14

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

3 enrolled 8 charts

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03484819 2025-03-03

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

12 enrolled 13 charts

Lymphoma, Large B-Cell, Diffuse

NCT03366272 2025-01-28

NIVEAU

Phase 2/3 Completed

348 enrolled

Lymphoma, Non-Hodgkin

NCT03061188 2024-06-12

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

15 enrolled 18 charts

Lymphoma, T-Cell, Lymphoma, Mantle-Cell

NCT03892044 2024-05-02

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

7 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03310619 2024-04-04

PLATFORM

62 enrolled 41 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02420912 2024-03-20

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

37 enrolled 12 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03927105 2024-03-18

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

4 enrolled 11 charts

Lymphoma, T-Cell, Peripheral

NCT03229278 2023-12-06

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

DermatologicGenitourinaryHead & NeckLymphoidThoracic

14 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Melanoma, Neoplasm Metastasis

NCT03436862 2023-12-05

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

37 enrolled 6 charts

Hodgkin Disease, Hematologic Neoplasms

NCT02181738 2023-11-28

CheckMate 205

294 enrolled 32 charts

Hodgkin Disease

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

CNSDermatologicLymphoidSarcoma

140 enrolled 23 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT04091490 2023-09-21

Nivo-DHAP

40 enrolled

Hodgkin Disease

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

37 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03305445 2023-02-15

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

6 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02572167 2022-11-08

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

93 enrolled 13 charts

Hodgkin Disease

NCT03580408 2022-08-19

Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma

64 enrolled

Hodgkin Disease, Lymphoma

NCT02038946 2022-01-04

Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

116 enrolled 14 charts

Lymphoma

NCT02857426 2021-12-23

CheckMate 647

66 enrolled 14 charts

Lymphoma

NCT02973113 2021-07-21

PREVALE

8 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders

NCT01822509 2021-06-24

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

LymphoidMyeloidOther hematologic neoplasmPlasma cell

71 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03259529 2021-06-07

BeGeRN

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04439214 2021-04-06

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

LymphoidOther hematologic neoplasmPlasma cell

47 enrolled 10 charts

Turcot syndrome, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT03343652 2020-05-28

NB001

30 enrolled

Hodgkin Disease

NCT03343665 2020-01-23

Nivo40

30 enrolled

Hodgkin Disease

NCT02518958 2019-11-18

PRIMETIME

12 enrolled